Print

Cell>Point Presents Phase 2 Clinical Trial Results Comparing its 99mTc-EC-G SPECT Cancer Imaging Agent to FDG PET at Society of Nuclear Medicine Annual Meeting June 7, 2011  
6/6/2011 10:34:08 AM

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine), used to diagnose and stage patients with Non-Small Cell Lung Cancer (NSCLC) at the 2011 Society of Nuclear Medicine Annual Meeting on June 7, 2011.
//-->